Biography
Biography: Daniela Pencheva
Abstract
The traditions of “Bul Bio-NCIPD” in the production of established vaccines as BCG, TETATOX, DIFTET, DIFTETKOK and TETADIF are longstanding. Produced is also PPD Tuberculin, ready to use for Mantoux’s intradermal test to assist in clinical diagnosis of tuberculosis. The improved from the WHO, vaccines give the ability for its distribution worldwide. Efforts are oriented to maintaining the quality of the approved production by meeting the requirements of GMP and ISO 9001: 2008 and at the same time to develop innovations focused on reducing side effects if possible by keeping the strength of the immune response to vaccination. Studied parallel were the possibilities for obtaining ghost vaccines using nanotechnology and obtaining transgenic bacteria with included therein viral genome. The scientific challenge in such developments is big and requires coordination of efforts of various specialists. Development of a vaccine for veterinary use of recombinant "ghost" cell carriers of bacterial and viral genome against causes of enteric disease is the basis of a draft proposal with great potential awaiting development and implementation. At first the minimal bactericidal concentration of PVA / AgNps was defined for each of the tested 4 Salmonella strains - two strains S. enteritidis, S. newport Puerto Rico and S. typhymurium. Rabbits were immunized with “ghost” Salmonella antigens. The existence of cross-reactive antigens was determined in the obtained rabbit sera. The joint O and/or H-antigens in some strains allow selection of smaller number of serotypes that will have extensive protective effect when they will be used in a "ghost" vaccine.